Sodium pentosan polysulphate as a polyanionic inhibitor of calcium oxalate crystallization in vitro and in vivo

R. W. Norman, D. S. Scurr, W. G. Robertson, Munro Peacock

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Studies in vitro showed that sodium pentosan polysulphate (SPP) is an active inhibitor of calcium oxalate crystal growth and agglomeration and that it acts by increasing the negative zeta potential on the surface of calcium oxalate crystals. Oral administration to human subjects resulted in an increase in the negative zeta potential, which is consistent with an increase in the polyanionic inhibitory activity of urine. SPP may offer a novel approach to the medical management of recurrent calcium oxalate stone disease.

Original languageEnglish (US)
Pages (from-to)369-371
Number of pages3
JournalClinical Science
Volume68
Issue number3
StatePublished - 1985
Externally publishedYes

Fingerprint

Pentosan Sulfuric Polyester
Calcium Oxalate
Crystallization
Oral Administration
Urine
In Vitro Techniques

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sodium pentosan polysulphate as a polyanionic inhibitor of calcium oxalate crystallization in vitro and in vivo. / Norman, R. W.; Scurr, D. S.; Robertson, W. G.; Peacock, Munro.

In: Clinical Science, Vol. 68, No. 3, 1985, p. 369-371.

Research output: Contribution to journalArticle

@article{8aeb1e44bf26452dbfab659ba6f92146,
title = "Sodium pentosan polysulphate as a polyanionic inhibitor of calcium oxalate crystallization in vitro and in vivo",
abstract = "Studies in vitro showed that sodium pentosan polysulphate (SPP) is an active inhibitor of calcium oxalate crystal growth and agglomeration and that it acts by increasing the negative zeta potential on the surface of calcium oxalate crystals. Oral administration to human subjects resulted in an increase in the negative zeta potential, which is consistent with an increase in the polyanionic inhibitory activity of urine. SPP may offer a novel approach to the medical management of recurrent calcium oxalate stone disease.",
author = "Norman, {R. W.} and Scurr, {D. S.} and Robertson, {W. G.} and Munro Peacock",
year = "1985",
language = "English (US)",
volume = "68",
pages = "369--371",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "3",

}

TY - JOUR

T1 - Sodium pentosan polysulphate as a polyanionic inhibitor of calcium oxalate crystallization in vitro and in vivo

AU - Norman, R. W.

AU - Scurr, D. S.

AU - Robertson, W. G.

AU - Peacock, Munro

PY - 1985

Y1 - 1985

N2 - Studies in vitro showed that sodium pentosan polysulphate (SPP) is an active inhibitor of calcium oxalate crystal growth and agglomeration and that it acts by increasing the negative zeta potential on the surface of calcium oxalate crystals. Oral administration to human subjects resulted in an increase in the negative zeta potential, which is consistent with an increase in the polyanionic inhibitory activity of urine. SPP may offer a novel approach to the medical management of recurrent calcium oxalate stone disease.

AB - Studies in vitro showed that sodium pentosan polysulphate (SPP) is an active inhibitor of calcium oxalate crystal growth and agglomeration and that it acts by increasing the negative zeta potential on the surface of calcium oxalate crystals. Oral administration to human subjects resulted in an increase in the negative zeta potential, which is consistent with an increase in the polyanionic inhibitory activity of urine. SPP may offer a novel approach to the medical management of recurrent calcium oxalate stone disease.

UR - http://www.scopus.com/inward/record.url?scp=0021924713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021924713&partnerID=8YFLogxK

M3 - Article

C2 - 2578913

AN - SCOPUS:0021924713

VL - 68

SP - 369

EP - 371

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 3

ER -